Search

Keywords: baricitinib; hand dermatitis; hand eczema; hyperkeratotic hand eczema; atopic hand eczema; JAK-inhibitor; treatment EN baricitinib hand dermatitis hand eczema hyperkeratotic hand eczema atopic hand eczema JAK-inhibitor treatment 419 421 3 04/14/22 20220501 NES 220501 Janus Kinase (JAK) inhibitors target the JAK and signal transducer and activator of transcription (STAT) signaling pathway that modulates T helper (Th)1, Th2, Th17, and Th22 signaling and is involved in many immune-mediated diseases. Hand dermatitis, hand eczema, treatment, baricitinib, hyperkeratotic hand eczema, atopic hand eczema, JAK-inhibitor. [Extracted from the article]

Keywords: dupilumab; hand dermatitis; hand eczema; hyperkeratotic hand eczema; treatment EN dupilumab hand dermatitis hand eczema hyperkeratotic hand eczema treatment 124 127 4 01/28/21 20210201 NES 210201 Dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4 and IL-13 signaling, is currently approved for the treatment of atopic dermatitis (AD). Effective treatment of hand eczema with dupilumab has been reported previously in case series, two small retrospective cohorts, and one prospective observational study including atopic, irritant and vesicular hand eczema subgroups.1-4 However, the effect of dupilumab on isolated hyperkeratotic hand eczema (HHE) has not yet been described. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. [Extracted from the article]